FDAAdvisoryCommittee.com
March 9, 2010 - Pulmonary-Allergy Drugs Advisory Committee
NDA - prifenidone (InterMune)
Agenda: On March 9, 2010, the committee will discuss new drug application (NDA) 22-535, pirfenidone, by InterMune. The proposed indication (purpose) of this drug is the treatment of patients with idiopathic pulmonary fibrosis (scarring of the lungs without a known cause to decrease the decline in lung function associated with this condition.
Please Click HERE for our current calendar of upcoming events
To sign up for the live webcast, go to http://fdaac.com
FDAAdvisoryCommittee.com
No comments:
Post a Comment